Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- (no title)
- Blood test helps predict myeloma relapse risk without biopsy
- The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
- MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
- Trial testing cell therapy for hard-to-treat AML now full in both countries
- Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review
- FDA approves electrical field therapy Optune Pax for pancreatic cancer
- (no title)
- (no title)
- Trial of glioma drug safusidenib to add patients, move to Phase 3